GP
BCYC

GSK plc’s Bicycle Therapeutics BCYC Stock Holding History

GSK plc’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.49M Hold
1,529,561
– – 1.08% 11
2026
Q1 		$7.1M Hold
1,529,561
– – 1.18% 11
2025
Q4 		$10.8M Buy
+1,529,561
New +$11.3M 1.36% 10

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GSK plc's BCYC Position: Q2 2026 in Review

GSK plc held its Bicycle Therapeutics (BCYC) position steady in Q2 2026 at 1,529,561 shares worth $6.49M. The position accounts for 1.08% of the portfolio, ranked #11.

GSK plc first reported a position in BCYC in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.8M in Q4 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • GSK plc held 1,529,561 shares of Bicycle Therapeutics worth $6.49M as of Q2 2026.
  • GSK plc left its Bicycle Therapeutics share count unchanged in Q2 2026.
  • Bicycle Therapeutics made up 1.08% of GSK plc's portfolio in Q2 2026, its #11 holding.
  • GSK plc first reported a position in Bicycle Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • GSK plc's Bicycle Therapeutics position peaked at $10.8M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on GSK plc's 13F filing for Q2 2026, filed 13 Aug 2026.